Garrett M Brodeur

List of Publications by Year
in descending order

127 papers	17,684 citations	36691 53 h-index	21239 119 g-index
130 all docs	130 docs citations	130 times ranked	12917 citing authors

#	Article	IF	Citations
1	Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models. International Journal of Molecular Sciences, 2022, 23, 1752.	1.8	3
2	Poloxamerâ€linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of highâ€risk neuroblastoma with primary and acquired chemoresistance. FASEB Journal, 2022, 36, e22213.	0.2	5
3	Abstract 5898: Bone morphogenic protein receptor 2 (BMPR2) as a potential germline driver in Juvenile Polyposis Syndrome (JPS). Cancer Research, 2022, 82, 5898-5898.	0.4	0
4	Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prevention Research, 2021, 14, 215-222.	0.7	26
5	Environment-Sensitive Polymeric Micelles Encapsulating SN-38 Potently Suppress Growth of Neuroblastoma Cells Exhibiting Intrinsic and Acquired Drug Resistance. ACS Pharmacology and Translational Science, 2021, 4, 240-247.	2.5	4
6	Nanomicellar Lenalidomideâ€“Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor . International Journal of Nanomedicine, 2020, Volume 15, 6873-6886.	3.3	4
7	Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors. Cancer Research, 2020, 80, 4258-4265.	0.4	9
8	Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. Molecular Cancer Therapeutics, 2020, 19, 920-926.	1.9	15
9	The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid Surveillance. Hormone Research in Paediatrics, 2020, 93, 634-642.	0.8	6
10	RET receptor expression and interaction with TRK receptors in neuroblastomas. Oncology Reports, 2020, 44, 263-272.	1.2	6
11	The effectiveness of Wilms tumor screening in Beckwithâ€“Wiedemann spectrum. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3115-3123.	1.2	25
12	Gain-of-Function STAT1 Mutation With Familial Lymphadenopathy and Hodgkin Lymphoma. Frontiers in Pediatrics, 2019, 7, 160.	0.9	9
13	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2019, 66, e27819.	0.8	20
14	A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model . Drug Design, Development and Therapy, 2019, Volume 13, 4305-4319.	2.0	13
15	Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. JCO Precision Oncology, 2019, 3, 1-26.	1.5	6
16	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology, 2019, 156, 273-274.	0.6	19
17	Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model. Clinical Cancer Research, 2018, 24, 2585-2593.	3.2	25
18	Spontaneous regression of neuroblastoma. Cell and Tissue Research, 2018, 372, 277-286.	1.5	149

#	Article	IF	Citations
19	Diagnosis of Beckwithâ€“Wiedemann syndrome in children presenting with Wilms tumor. Pediatric Blood and Cancer, 2018, 65, e27296.	0.8	32
20	Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.. Journal of Clinical Oncology, 2018, 36, 10536-10536.	0.8	10
21	Colorectal cancer risk in Li-Fraumeni syndrome: Is it time for earlier surveillance?. Journal of Clinical Oncology, 2018, 36, e13503-e13503.	0.8	0
22	Management of adrenal masses in patients with Beckwithâ€“Wiedemann syndrome. Pediatric Blood and Cancer, 2017, 64, e26432.	0.8	22
23	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67.	3.2	139
24	Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. Clinical Cancer Research, 2017, 23, e1-e5.	3.2	130
25	The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass. Clinical Cancer Research, 2017, 23, e133-e137.	3.2	29
26	Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical Cancer Research, 2017, 23, e98-e106.	3.2	166
27	Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget, 2016, 7, 15977-15985.	0.8	20
28	The â€œneuroâ€•of neuroblastoma: <scp>N</scp>euroblastoma as a neurodevelopmental disorder. Annals of Neurology, 2016, 80, 13-23.	2.8	54
29	Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer, 2016, 122, 935-945.	2.0	58
30	Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Letters, 2016, 372, 179-186.	3.2	63
31	Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma. Molecular Cancer, 2015, 14, 150.	7.9	21
32	Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Letters, 2015, 360, 205-212.	3.2	32
33	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. MedChemComm, 2015, 6, 2184-2193.	3.5	19
34	Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials, 2015, 51, 22-29.	5.7	36
35	TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemotherapy and Pharmacology, 2015, 75, 131-141.	1.1	32
36	The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex. Biochemical Journal, 2015, 468, 345-352.	1.7	36

#	Article	IF	Citations
37	Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines. In Vitro Cellular and Developmental Biology - Animal, 2014, 50, 188-193.	0.7	8
38	Therapeutic targets for neuroblastomas. Expert Opinion on Therapeutic Targets, 2014, 18, 277-292.	1.5	43
39	Mechanisms of neuroblastoma regression. Nature Reviews Clinical Oncology, 2014, 11, 704-713.	12.5	228
40	Role of CHD5 in Human Cancers: 10 Years Later. Cancer Research, 2014, 74, 652-658.	0.4	77
41	CHD5 is required for spermiogenesis and chromatin condensation. Mechanisms of Development, 2014, 131, 35-46.	1.7	69
42	Epigenetic silencing of CHD5, a novel tumorâ€suppressor gene, occurs in early colorectal cancer stages. Cancer, 2014, 120, 172-180.	2.0	51
43	Mechanisms of CHD5 Inactivation in Neuroblastomas. Clinical Cancer Research, 2012, 18, 1588-1597.	3.2	60
44	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 2012-2023.	3.2	59
45	AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemotherapy and Pharmacology, 2012, 70, 477-486.	1.1	22
46	Clinical significance of NTRK family gene expression in neuroblastomas. Pediatric Blood and Cancer, 2012, 59, 226-232.	0.8	33
47	Identifying TRKA and TRKB specific pathways in neuroblastoma through phosphoproteomic analysis.. Journal of Clinical Oncology, 2012, 30, e20008-e20008.	0.8	0
48	The effect of P75 on Trk receptors in neuroblastomas. Cancer Letters, 2011, 305, 76-85.	3.2	27
49	Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemotherapy and Pharmacology, 2011, 68, 1057-1065.	1.1	76
50	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1469-1475.	1.1	16
51	Knowing Your ABCCs: Novel Functions of ABCC Transporters. Journal of the National Cancer Institute, 2011, 103, 1207-1208.	3.0	4
52	Getting Into the AKT. Journal of the National Cancer Institute, 2010, 102, 747-749.	3.0	5
53	Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma. Clinical Cancer Research, 2010, 16, 1478-1485.	3.2	56
54	The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 298-303.	0.8	869

#	Article	IF	Citations
55	Trk Receptor Expression and Inhibition in Neuroblastomas. Clinical Cancer Research, 2009, 15, 3244-3250.	3.2	258
56	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 289-297.	0.8	1,540
57	Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008, 455, 930-935.	13.7	1,207
58	A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene. Molecular Cancer Research, 2008, 6, 735-742.	1.5	298
59	CHD5 , a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas. Journal of the National Cancer Institute, 2008, 100, 940-949.	3.0	164
60	Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 913-918.	0.8	67
61	Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number. Cancer Research, 2006, 66, 6050-6062.	0.4	178
62	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene, 2005, 24, 2684-2694.	2.6	147
63	Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6466-6473.	0.8	135
64	Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 9868-9875.	0.4	122
65	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. Journal of Clinical Oncology, 2005, 23, 8819-8827.	0.8	74
66	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine, 2005, 353, 2243-2253.	13.9	495
67	CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene, 2003, 22, 1002-1011.	2.6	145
68	Neuroblastoma: biological insights into a clinical enigma. Nature Reviews Cancer, 2003, 3, 203-216.	12.8	1,871
69	Significance of intratumoral genetic heterogeneity in neuroblastomas. Medical and Pediatric Oncology, 2002, 38, 112-113.	1.0	18
70	Significance of intratumoral genetic heterogeneity in neuroblastomas. , 2002, 38, 112.		1
71	Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Research, 2002, 62, 1802-8.	0.4	81
72	Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research, 2002, 62, 6462-6.	0.4	182

#	Article	IF	Citations
73	Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Research, 2002, 62, 6651-8.	0.4	65
74	Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilmsâ€™ Tumor. Journal of Clinical Oncology, 2001, 19, 689-696.	0.8	99
75	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies?a report from the children's cancer group study. Medical and Pediatric Oncology, 2001, 36, 612-622.	1.0	203
76	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer, 2001, 92, 2699-2708.	2.0	132
77	TrkA signal transduction pathways in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 108-110.	1.0	11
78	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 24-27.	1.0	48
79	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 32-36.	1.0	63
80	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 52-55.	1.0	16
81	Association amongEPHB2, TrkA, andMYCN expression in low-stage neuroblastomas. Medical and Pediatric Oncology, 2001, 36, 80-82.	1.0	19
82	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. , 2001, 92, 2699.		1
83	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 512-515.	1.0	25
84	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology, 2000, 35, 526-530.	1.0	26
85	Deletion of 11q23 is a frequent event in the evolution ofMYCN single-copy high-risk neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 544-546.	1.0	37
86	Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 569-572.	1.0	31
87	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. Medical and Pediatric Oncology, 2000, 35, 573-576.	1.0	27
88	Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo. Medical and Pediatric Oncology, 2000, 35, 590-592.	1.0	6
89	Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Medical and Pediatric Oncology, 2000, 35, 603-607.	1.0	61
90	Prognostic significance ofEPHB6, EFNB2, andEFNB3 expressions in neuroblastoma. Medical and Pediatric Oncology, 2000, 35, 656-658.	1.0	25

#	Article	IF	Citations
91	Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene, 2000, 19, 2043-2051.	2.6	86
92	Relative Quantitative RT-PCR Protocol for TrkB Expression in Neuroblastoma Using GAPD as an Internal Control. BioTechniques, 2000, 28, 681-691.	0.8	31
93	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1888-1899.	0.8	146
94	Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1260-1268.	0.8	212
95	Different effects of TrkA expression in neuroblastoma cell lines with or withoutMYCN amplification. Medical and Pediatric Oncology, 2000, 35, 623-627.	1.0	17
96	Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene, 2000, 19, 4604-4610.	2.6	169
97	p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. , 2000, 35, 573.		2
98	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 1999, 18, 4948-4957.	2.6	228
99	Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. New England Journal of Medicine, 1999, 341, 1165-1173.	13.9	1,722
100	Role of Apoptosis in Human Neuroblastomas. , 1999, , 305-318.		3
101	A variant transcript encoding an isoform of the human protein tyrosine kinase EPHB2 is generated by alternative splicing and alternative use of polyadenylation signals. Oncogene, 1998, 17, 521-526.	2.6	9
102	Biological aspects of neuroblastoma screening. Medical and Pediatric Oncology, 1998, 31, 394-400.	1.0	14
103	MYCN Is the only highly expressed gene from the core amplified domain in human neuroblastomas. , 1998, 23, 134-140.		22
104	Biological aspects of neuroblastoma screening. Medical and Pediatric Oncology, 1998, 31, 394-400.	1.0	1
105	Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene, 1997, 15, 1937-1946.	2.6	29
106	Expression of TrkA, TrkB and TrkC in human neuroblastomas. Journal of Neuro-Oncology, 1997, 31, 49-56.	1.4	127
107	Familial neuroblastoma: A three-generation pedigree and a further association with Hirschsprung disease. , 1997, 28, 1-5.		40
108	Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. , 1997, 19, 176-184.		48

#	Article	IF	Citations
109	Biology and Genetics of Human Neuroblastomas. The American Journal of Pediatric Hematology/oncology, 1997, 19, 93-101.	1.3	205
110	High-Resolution Mapping of a 130-kb Core Region of theMYCNAmplicon in Neuroblastomas. Genomics, 1996, 32, 97-103.	1.3	39
111	Co-amplification and concomitant high levels of expression of a DEAD box gene withMYCN in human neuroblastoma. Genes Chromosomes and Cancer, 1995, 14, 196-203.	1.5	56
112	Do the ends justify the means?. Nature Medicine, 1995, 1, 203-205.	15.2	8
113	Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated human protein–tyrosine kinase gene of the EPH family. Human Molecular Genetics, 1995, 4, 2033-2045.	1.4	26
114	Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics, 1995, 25, 538-546.	1.3	88
115	Molecular Analysis of Gene Amplification in Tumors. Current Protocols in Human Genetics, 1994, 2, Unit 10.5.	3.5	3
116	Correlation between morphologic and other prognostic markers of neuroblastoma a study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the pediatric oncology group. Cancer, 1993, 71, 3173-3181.	2.0	53
117	Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer, 1993, 72, 3346-3354.	2.0	43
118	Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma. Genes Chromosomes and Cancer, 1993, 7, 102-108.	1.5	29
119	Preferential amplification of the paternal allele of the Nâ€“myc gene in human neuroblastomas. Nature Genetics, 1993, 4, 191-194.	9.4	65
120	Association between High Levels of Expression of the TRK Gene and Favorable Outcome in Human Neuroblastoma. New England Journal of Medicine, 1993, 328, 847-854.	13.9	639
121	Molecular Basis of Clinical Heterogeneity in Neuroblastoma. Journal of Pediatric Hematology/Oncology, 1992, 14, 111-116.	0.3	127
122	Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer, 1992, 70, 1685-1694.	2.0	134
123	Biology of tumors of the peripheral nervous system. Cancer and Metastasis Reviews, 1991, 10, 321-333.	2.7	8
124	Neuroblastoma -Clinical Applications of Molecular Parameters. Brain Pathology, 1990, 1, 47-54.	2.1	34
125	Molecular biology and genetics of human neuroblastoma. Cancer Genetics and Cytogenetics, 1989, 41, 153-174.	1.0	176
126	Clinical implications of oncogene activation in human neuroblastomas. Cancer, 1986, 58, 541-545.	2.0	68

#	Article	IF	Citations
127	Association of Multiple Copies of the N-mycOncogene with Rapid Progression of Neuroblastomas. New England Journal of Medicine, 1985, 313, 1111-1116.	13.9	1,853